Connect to other sites within the UBM Medica Network
Life Expectancy in CML Patients Approaching General Population’s
A study covering 4 decades of patients with chronic myeloid leukemia in Sweden found dramatic improvements in life expectancy since the advent of tyrosine kinase inhibitor therapy.
CML Patients on TKIs May Have Increased Risk of Thromboembolic Events
Patients with chronic myeloid leukemia who are treated with tyrosine kinase inhibitors could be at increased risk of long-term cardiovascular toxicity.
Early TKI Responses Predict CML Survival, Especially With Dasatinib
Two studies show that early deep responses with TKIs yield lasting positive outcomes in CML patients, and that dasatinib outperforms imatinib.
Five-Year Results Support First-Line Dasatinib Use in CML
A 5-year analysis of the DASISION trial showed that dasatinib continued to offer better responses than imatinib in patients with chronic myeloid leukemia.
Prior Malignancies, Autoimmune Disorders Increased in CML Patients
Chronic myeloid leukemia patients had a significantly increased prevalence of prior malignancies and autoimmune disorders compared with the general population.
PegIFN Improves Responses to Dasatinib in Newly Diagnosed CML Patients
The addition of pegylated interferon-ɑ2b to dasatinib yielded promising results in a small trial of newly diagnosed chronic myeloid leukemia patients.
Vascular Events Remain a Problem for Ponatinib in CML
The efficacy of ponatinib in patients with newly diagnosed CML compared with imatinib remains to be established, as a randomized phase III trial was terminated early due to concerns regarding arterial occlusive events with ponatinib.
By clicking Accept, you agree to become a member of the UBM Medica Community.